KPX Lifescience.Co.Ltd (114450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has a cash flow conversion efficiency ratio of 0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.33 Billion ≈ $2.26 Million USD) by net assets (₩35.13 Billion ≈ $23.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 114450 net asset quality score to measure how much of total assets are equity-financed.
KPX Lifescience.Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 114450 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
KPX Lifescience.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
Ken Holdings Bhd
KLSE:7323
|
0.018x |
|
Renewables Infrastructure Grp
LSE:TRIG
|
0.021x |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
0.022x |
|
NanoViricides Inc
NYSE MKT:NNVC
|
-0.222x |
|
BRAINCOOL AB
F:5YL
|
-0.135x |
|
Northstar Clean Technologies Inc
V:ROOF
|
0.233x |
|
Sephaku Holdings Ltd
JSE:SEP
|
0.054x |
Annual Cash Flow Conversion Efficiency for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 114450 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.75 Billion ≈ $24.23 Million |
₩525.49 Million ≈ $356.12K |
0.015x | +42.84% |
| 2023-12-31 | ₩35.95 Billion ≈ $24.37 Million |
₩370.02 Million ≈ $250.76K |
0.010x | +111.90% |
| 2022-12-31 | ₩52.64 Billion ≈ $35.67 Million |
₩-4.55 Billion ≈ $-3.08 Million |
-0.086x | -896.27% |
| 2021-12-31 | ₩56.30 Billion ≈ $38.15 Million |
₩611.38 Million ≈ $414.33K |
0.011x | -66.11% |
| 2020-12-31 | ₩59.37 Billion ≈ $40.23 Million |
₩1.90 Billion ≈ $1.29 Million |
0.032x | -54.41% |
| 2019-12-31 | ₩60.36 Billion ≈ $40.90 Million |
₩4.24 Billion ≈ $2.87 Million |
0.070x | -22.75% |
| 2018-12-31 | ₩59.11 Billion ≈ $40.06 Million |
₩5.38 Billion ≈ $3.64 Million |
0.091x | -0.57% |
| 2017-12-31 | ₩62.09 Billion ≈ $42.08 Million |
₩5.68 Billion ≈ $3.85 Million |
0.091x | -20.17% |
| 2016-12-31 | ₩61.66 Billion ≈ $41.79 Million |
₩7.07 Billion ≈ $4.79 Million |
0.115x | +16.09% |
| 2015-12-31 | ₩56.90 Billion ≈ $38.56 Million |
₩5.62 Billion ≈ $3.81 Million |
0.099x | +24.53% |
| 2014-12-31 | ₩51.53 Billion ≈ $34.92 Million |
₩4.09 Billion ≈ $2.77 Million |
0.079x | -- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more